Zentalis Pharmaceuticals (NASDAQ:ZNTL) Now Covered by Rodman & Renshaw

Rodman & Renshaw started coverage on shares of Zentalis Pharmaceuticals (NASDAQ:ZNTL) in a research note published on Thursday morning, MarketBeat Ratings reports. The firm issued a buy rating and a $11.00 target price on the stock.

A number of other research analysts have also weighed in on ZNTL. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd. Guggenheim upped their price target on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a report on Friday, April 10th. Wall Street Zen raised Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Mizuho initiated coverage on Zentalis Pharmaceuticals in a research note on Friday, July 17th. They set an “outperform” rating and a $8.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Four investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Zentalis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $6.75.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $4.45 on Thursday. Zentalis Pharmaceuticals has a fifty-two week low of $1.21 and a fifty-two week high of $6.95. The firm has a market capitalization of $316.80 million, a PE ratio of -2.57 and a beta of 1.92. The company’s 50-day moving average is $4.15 and its 200 day moving average is $3.46.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.01). As a group, analysts expect that Zentalis Pharmaceuticals will post -1.83 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. AQR Capital Management LLC increased its holdings in Zentalis Pharmaceuticals by 177.6% in the 1st quarter. AQR Capital Management LLC now owns 619,330 shares of the company’s stock worth $985,000 after acquiring an additional 396,233 shares during the last quarter. Millennium Management LLC lifted its holdings in Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock valued at $4,881,000 after purchasing an additional 2,111,951 shares during the last quarter. Qube Research & Technologies Ltd purchased a new stake in Zentalis Pharmaceuticals during the second quarter valued at about $37,000. Sei Investments Co. boosted its position in Zentalis Pharmaceuticals by 373.1% during the second quarter. Sei Investments Co. now owns 167,100 shares of the company’s stock worth $194,000 after purchasing an additional 131,780 shares during the period. Finally, Jane Street Group LLC increased its stake in shares of Zentalis Pharmaceuticals by 346.3% in the second quarter. Jane Street Group LLC now owns 664,061 shares of the company’s stock worth $770,000 after purchasing an additional 515,257 shares in the last quarter.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.